查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
疫苗佐剂市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按佐剂类别、类型和地理位置
市场调查报告书
商品编码
1424131

疫苗佐剂市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按佐剂类别、类型和地理位置

Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography
出版日期: | 出版商: The Insight Partners | 英文 155 Pages | 订单完成后即时交付

价格

疫苗佐剂市场预计将从2022年的24.82亿美元成长到2028年的69.31亿美元；预计 2022 年至 2028 年CAGR为13.7%。对佐剂研究发展的支持和产品发布的合作努力为疫苗佐剂市场创造了机会，这是推动疫苗佐剂市场增长的有影响力的市场成长的独立因素。

佐剂是添加到疫苗製剂中的成分，可以使接受疫苗的人产生更强的免疫反应。传染病爆发和大流行的增加以及兽用疫苗佐剂的监管批准是推动市场发展的关键因素。然而，产品召回和不良影响阻碍了疫苗佐剂市场的成长。

成长动力：

支持佐剂研究的发展和产品上市的合作努力为疫苗佐剂市场创造机会

美国国家过敏和传染病研究所 (NIAID) 在开发、发现和表征新型疫苗佐剂方面发挥重要作用。该研究所在提高现有疫苗的功效、针对现有和新出现的传染病设计新的或更好的疫苗以及开发治疗过敏、自体免疫疾病和癌症的疫苗方面发挥着至关重要的作用。此外，NIAID的疫苗佐剂研究计画旨在开发一套佐剂，包括可以与抗原匹配以优化最终疫苗功效的候选剂。因此，为了促进NIAID 支持的疫苗佐剂研究人员与更广泛的科学界之间的合作，NIAID 于2020 年建立了疫苗佐剂纲要(VAC)。这个基于网络的工具显示佐剂特征，以帮助疫苗开发人员识别适合其目标疾病的佐剂。

SK Biosciences 和 GSK 等疫苗业务公司正在透过实施合作等成长策略来大规模生产佐剂，以满足全球需求。例如，2022 年 4 月，SK Biosciences 和 GSK 在 3 期临床试验获得积极资料后宣布向韩国食品药物安全部 (KMFDS) 提交 SKYCovione 的生物许可申请。因此，各政府部门为促进疫苗佐剂研发提供的支援、顶级製造商之间的合作以及透过此类合作业务策略推出创新产品可能会在预测期内为疫苗佐剂市场的成长提供利润丰厚的机会。

按佐剂类别，矿物盐佐剂细分市场在 2022 年占据疫苗佐剂市场的最大份额。乳剂佐剂细分市场预计在预测期内将以 14.6% 的最快CAGR增长。矿物盐如不溶性铝盐和磷酸钙在疫苗製剂中用作佐剂。铝盐佐剂有助于诱导早期和持久的保护性免疫力。用于人类疫苗的铝佐剂受到美国食品药物管理局 (FDA) 的监管，添加少量的铝可以帮助人体建立比疫苗中单独抗原更高的免疫原性。发炎部位的矿物盐佐剂配方透过释放促发炎细胞激素产生快速免疫反应。因此，矿物盐佐剂诱导针对抗原的快速免疫反应的能力有利于疫苗佐剂市场的成长。

2022年，北美贡献了全球最大的疫苗佐剂市场。预计亚太地区 2022 年至 2030 年CAGR最高。疫苗佐剂产品审批的加速促进了北美市场的成长。此外，生产助剂的顶级製造商的存在进一步促进了整体市场的成长。

快速的产品审批流程有利于美国的疫苗佐剂市场。 2023年5月，葛兰素史克（GSK）的Arexvy（呼吸道合胞病毒疫苗，佐剂）获得美国食品药物管理局（FDA）批准，旨在预防呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD） 。因此，Arexvy 成为世界上第一个 FDA 批准的针对老年人的 RSV 疫苗。 2022 年 10 月，Novavax, Inc. 的 COVID-19 佐剂疫苗获得 FDA 的紧急使用授权 (EUA)，该疫苗可作为成年患者的加强疫苗。

产业发展及未来机会：

以下列出了疫苗佐剂市场领导企业的各种策略发展：

2022 年 4 月，GSK plc 和 SK Bioscience 提交了 SKYCovione 的生物製品许可申请，​​SKYCovione 是一种基于重组蛋白的佐剂 COVID-19 候选疫苗。它含有葛兰素史克的大流行佐剂。在 III 期临床试验获得积极资料后，这些公司已向韩国食品药品安全部提交了生物製品许可申请。

2021年11月，Seppic推出了MONTANIDE GEL P PR，这是一种基于聚合物技术的水性佐剂，专门用于禽类注射疫苗，满足禽类市场对无害性的需求。此外，MONTANIDE GEL P PR 特别稳定，可抵抗禽类疫苗中常用的不稳定抗原介质。

2023 年10 月，SPI Pharma Inc. 和Q-Vant Biosciences Inc. 宣布建立合作伙伴关係，将Q-Vant 在永续皂苷萃取技术方面的领先地位与SPI 在製药业的全球影响力和服务专业知识结合起来。该安排包括投资扩大 Q-Vant 专有的 100% 可持续 Q-SAP 技术，以及一项独家商业协议，以加速其皂苷佐剂在兽医和人类疫苗配方中的全球采用。

2023 年 1 月，韩国食品药物安全部 (KMFDS) 授予 SK Bioscience NuvaxovidTM 增强型生产和行销授权，作为加强剂给 18 岁及以上的成年人服用。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：疫苗佐剂市场格局

  • PEST分析

第 5 章：疫苗佐剂市场 - 主要市场动态

  • 疫苗佐剂市场 - 主要市场动态
  • 市场驱动因素
    • 传染病爆发和大流行的数量不断增加
    • 兽用疫苗佐剂的核准
  • 市场限制
    • 产品召回和不良影响
  • 市场机会
    • 支持佐剂研究的发展和产品发布的合作努力
  • 未来的趋势
    • 技术进步
  • 驱动因素和限制的影响：

第 6 章：疫苗佐剂市场 - 全球市场分析

  • 疫苗佐剂市场收入，2022-2030
    • 概述
  • 疫苗佐剂市场 - 收入和 2030 年预测

第 7 章：疫苗佐剂市场分析 - 依佐剂类别

  • 概述
  • 矿物盐佐剂
  • 乳化助剂
  • 脂质体佐剂
  • 其他的

第 8 章：疫苗佐剂市场分析 - 按类型

  • 人类疫苗佐剂
  • 兽用疫苗佐剂

第 9 章：疫苗佐剂市场 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 10 章：产业格局

  • 概述
  • 全球疫苗佐剂市场的成长策略
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第 11 章：公司简介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Hawaii Biotech Inc
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 12 章：附录

Product Code: TIPRE00004430

The vaccine adjuvants market is expected to grow from US$ 2.482 billion in 2022 to US$ 6.931 billion by 2028; it is expected to grow at a CAGR of 13.7% from 2022 to 2028. Support for developments in adjuvant studies and collaborative efforts for product launches creates opportunities for the vaccine adjuvant market, a standalone factor responsible for influential market growth driving the vaccine adjuvants market growth.

An adjuvant is a component added to vaccine preparations to create a stronger immune response in people receiving the vaccine. The rising occurrence of infectious disease outbreaks and pandemics and regulatory approvals of veterinary vaccine adjuvants are the key factors propelling the market development. However, product recall and adverse effects hamper the vaccine adjuvant market growth.

Growth Drivers:

Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches Creates Opportunities for Vaccine Adjuvant Market

The National Institute of Allergy and Infectious Disease (NIAID) plays an important role in developing, discovering, and characterizing new vaccine adjuvants. The institute plays a crucial role in improving the efficacy of current vaccines, designing new or better vaccines against existing and emerging infectious diseases, and developing vaccines to treat allergies, autoimmune diseases, and cancer. Additionally, NIAID's vaccine adjuvant research program aims to develop a set of adjuvants, including candidates that can be matched with antigens to optimize the final vaccine efficacy. Therefore, to foster the collaboration between NIAID-supported vaccine adjuvant researchers and a broader scientific community, NIAID established the Vaccine Adjuvant Compendium (VAC) in 2020. This web-based tool displays adjuvant characteristics to help vaccine developers identify adjuvants suitable for their target disease.

Companies in the vaccine business, such as SK Biosciences and GSK, are producing adjuvants on a large scale to meet global demand by implementing growth strategies such as collaborations. For instance, in April 2022, SK Biosciences and GSK announced the submission of a biological license application for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) following positive data obtained in Phase 3 clinical trials. Therefore, the support provided by various government authorities to foster vaccine adjuvant research and development, collaborations between top manufacturers, and innovative product launches through such collaborative business strategies are likely to provide lucrative opportunities for the growth of the vaccine adjuvants market during the forecast period.

The mineral salt adjuvant segment held the largest share of the vaccine adjuvant market by adjuvant class 2022. The market for the emulsion adjuvant segment is anticipated to grow at the fastest CAGR of 14.6% during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvant formulation at the inflammatory site produces a fast immune response by releasing pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.

In 2022, North America contributed the largest global vaccine adjuvant market share. Asia Pacific is expected to register the highest CAGR during 2022-2030. Accelerated product approvals for vaccine adjuvants bolster market growth in North America. Additionally, the presence of top manufacturers producing adjuvants further enhances the overall market growth.

Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

Industry Developments and Future Opportunities:

Various strategic developments by leading players operating in the vaccine adjuvant market are listed below:

In April 2022, GSK plc and SK Bioscience submitted a biologics license application for SKYCovione, a recombinant protein-based, adjuvanted COVID-19 vaccine candidate. It contains GSK's pandemic adjuvant. The companies have submitted a biologics license application to the Korean Ministry of Food and Drug Safety following the positive data obtained in Phase III clinical trials.

In November 2021, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.

In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.

In January 2023, the Korean Ministry of Food and Drug Safety (KMFDS) granted SK Bioscience enhanced manufacturing and marketing authorization for NuvaxovidTM to be administered to adults aged 18 and above as a booster.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Vaccine Adjuvants Market Landscape

  • 4.1 PEST Analysis

5. Vaccine Adjuvants Market - Key Market Dynamics

  • 5.1 Vaccine Adjuvants Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 5.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 5.3 Market Restraints
    • 5.3.1 Product Recalls and Adverse Effects
  • 5.4 Market Opportunity
    • 5.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements
  • 5.6 Impact of Drivers and Restraints:

6. Vaccine Adjuvants Market - Global Market Analysis

  • 6.1 Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
    • 6.1.1 Overview
  • 6.2 Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 7.1 Overview
  • 7.2 Mineral Salt Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Emulsion Adjuvant
    • 7.3.1 Overview
    • 7.3.2 Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Liposome Adjuvant
    • 7.4.1 Overview
    • 7.4.2 Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Vaccine Adjuvants Market Analysis - by Type

  • 8.1 Human Vaccine Adjuvant
    • 8.1.1 Overview
    • 8.1.2 Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Veterinary Vaccine Adjuvant
    • 8.2.1 Overview
    • 8.2.2 Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Vaccine Adjuvants Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Vaccine Adjuvants Market Overview
    • 9.1.2 North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.2.1 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.1.2.2 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.1.3 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.1.3.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.1 Overview
        • 9.1.3.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.1 Overview
        • 9.1.3.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.1 Overview
        • 9.1.3.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type
  • 9.2 Europe
    • 9.2.1 Europe Vaccine Adjuvants Market Overview
    • 9.2.2 Europe: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
      • 9.2.2.1 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.2.2.2 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.2.3 Europe: Vaccine Adjuvants Market
      • 9.2.3.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.1 Overview
        • 9.2.3.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.1 Overview
        • 9.2.3.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.1 Overview
        • 9.2.3.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.1 Overview
        • 9.2.3.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.1 Overview
        • 9.2.3.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.6 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.1 Overview
        • 9.2.3.6.2 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.3 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.6.4 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Type
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Vaccine Adjuvants Market Overview
    • 9.3.2 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.2.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.3.3 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.3.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.3.4 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.3.4.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.1 Overview
        • 9.3.4.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.1 Overview
        • 9.3.4.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.1 Overview
        • 9.3.4.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.1 Overview
        • 9.3.4.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.1 Overview
        • 9.3.4.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.1 Overview
        • 9.3.4.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Vaccine Adjuvants Market Overview
    • 9.4.2 Middle East and Africa: Vaccine Adjuvants Market
      • 9.4.2.1 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.4.2.2 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.4.3 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.1 Overview
        • 9.4.3.1.2 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.1 Overview
        • 9.4.3.2.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.3 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.1 Overview
        • 9.4.3.3.2 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.4 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.1 Overview
        • 9.4.3.4.2 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.3 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.4.4 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Type
  • 9.5 South and Central America
    • 9.5.1 South and Central America Vaccine Adjuvants Market Overview
    • 9.5.2 South and Central America: Vaccine Adjuvants Market
      • 9.5.2.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.5.3 South and Central America: Vaccine Adjuvants Market
      • 9.5.3.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.5.4 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.5.4.1 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.1 Overview
        • 9.5.4.1.2 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.3 Brazil: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.1.4 Brazil: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.1 Overview
        • 9.5.4.2.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.3 Argentina: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.2.4 Argentina: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.3 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.1 Overview
        • 9.5.4.3.2 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.3 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.3.4 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Type

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 10.3 Organic Developments
    • 10.3.1 Overview
  • 10.4 Inorganic Developments
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 SPI Pharma Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 GSK Plc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 THREATS
    • 11.2.7 Key Developments
  • 11.3 CSL Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Seppic SA
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Hawaii Biotech Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies Corp
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 InvivoGen SAS
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Croda International Plc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Novavax Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Phibro Animal Health Corp
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.1 Glossary of Terms

List Of Tables

  • Table 1. Vaccine Adjuvants Market Segmentation
  • Table 2. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 3. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 4. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 5. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 6. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 7. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 8. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 9. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 10. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 11. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 13. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 14. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 15. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 16. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 17. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 18. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 19. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 20. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 21. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 23. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 24. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 25. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 26. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 27. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 28. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 29. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 30. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 31. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 33. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 34. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 35. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 36. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 38. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 39. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 40. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 43. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 44. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 45. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 46. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 47. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 48. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 49. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 50. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 51. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 52. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 53. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 54. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 55. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 56. Organic Developments Done by Companies
  • Table 57. Inorganic Developments Done by Companies
  • Table 58. Glossary of Terms, Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Vaccine Adjuvants Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 5. Vaccines Adjuvants Market, By Geography Forecast Analysis, 2022 & 2030
  • Figure 6. Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 7. Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 12. Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America: Vaccine Adjuvants Market by Key Countries - Revenue (2022) US$ Million
  • Figure 15. North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 17. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Europe: Vaccine Adjuvants Market - Revenue by Key Countries Revenue 2022 (US$ Million)
  • Figure 21. Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Europe: Vaccine Adjuvants Market (2022 and 2030)
  • Figure 23. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 26. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 27. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Asia Pacific: Vaccine Adjuvants Market - Revenue by Key Countries 2022 (US$ Million)
  • Figure 30. Asia Pacific: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 32. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 34. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 35. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 36. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 38. Middle East and Africa: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 39. Middle East and Africa: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 43. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 44. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 45. South and Central America: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 46. South and Central America: Vaccine Adjuvants Market, Revenue and Forecast to 2030 (US$ Million)
  • Figure 47. South and Central America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 48. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 49. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 50. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 51. Growth Strategies in the Global Vaccine Adjuvants Market